US Stocks

Gossamer Bio, Inc.

Gossamer Bio is a US-based biopharmaceutical company that develops and commercializes treatments for immunology, inflammation, and oncology. The company has developed multiple oral and inhaled small-molecule inhibitors such as GB002, GB004, GB5121, and GB7208 for the treatment of various diseases, such as pulmonary arterial hypertension, inflammatory bowel disease, primary central nervous system lymphoma, and multiple sclerosis. Gossamer Bio has license agreements with Pulmokine, Inc. and Aerpio Pharmaceuticals, Inc. for the development and commercialization of GB002, GB004, and related compounds.